Synonyms: ABBOTT-43818 | Camcevi® | Fensolvi® (leuprolide acetate injectable suspension) | Lupron® | TAP-144
leuprolide is an approved drug (FDA (1985))
Compound class:
Peptide or derivative
Comment: The marketed formulation contains leuprolide acetate.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
No information available. |
Summary of Clinical Use |
Used in the treatment of advanced prostate cancer, uterine fibroids and endometriosis, and may also be used to treat precocious puberty. In May 2019 the FDA approved an injectable suspension (Fensolvi®) to treat pediatric patients (≥2 yrs old) with central precocious puberty (CPP). EMA approval for the treament of prostatic neoplasms was issued in 2022 (for Accord Healthcare's product Camcevi®). |
Mechanism Of Action and Pharmacodynamic Effects |
Leuprolide is a synthetic GnRH receptor agonist. Sustained activation by GnRH agonists leads to down-regulation of receptor activity, decreased gonadotrophin secretion and reduced steroidogenesis. |
External links |
For extended ADME data see the following: Drugs.com |